Authors: | Hameed, M.; Dorfman, H. |
Article Title: | Primary malignant bone tumors-recent developments |
Abstract: | Primary malignant bone tumors are rare sarcomas with an estimated frequency of about 2900 new cases per year; they constitute less than 0.2% of all cancers diagnosed in the United States. The diagnosis and management of these neoplasms require a team approach, which includes orthopaedic surgeons, radiologists, pathologists, and oncologists. With this approach and current treatment modalities, the 5-year survival for the most common malignant bone tumors, osteosarcoma and Ewing sarcoma, are 70% and 60%, respectively. This review will summarize recent developments and advances in molecular pathogenesis of the more common primary malignant bone neoplasms. © 2011. |
Keywords: | immunohistochemistry; osteosarcoma; signal transduction; somatomedin; survival rate; gene translocation; overall survival; disease course; raf protein; antineoplastic agent; cancer grading; cell proliferation; cell survival; protein bcl 2; reverse transcription polymerase chain reaction; apoptosis; genetic association; genetic variability; diagnostic imaging; immunoreactivity; protein p53; carcinogenesis; ewing sarcoma; cancer genetics; mammalian target of rapamycin; ras protein; sex difference; upregulation; cyclin dependent kinase inhibitor 2a; genetic predisposition; karyotype; comparative genomic hybridization; diaphysis; chondrosarcoma; chordoma; cyclin dependent kinase 4; myogenin; genetic heterogeneity; cryotherapy; molecular pathology; molecular diagnosis; figitumumab; fibroblast growth factor receptor |
Journal Title: | Seminars in Diagnostic Pathology |
Volume: | 28 |
Issue: | 1 |
ISSN: | 0740-2570 |
Publisher: | Elsevier Inc. |
Date Published: | 2011-02-01 |
Start Page: | 86 |
End Page: | 101 |
Language: | English |
DOI: | 10.1053/j.semdp.2011.02.002 |
PROVIDER: | scopus |
PUBMED: | 21675380 |
DOI/URL: | |
Notes: | --- - "Export Date: 23 June 2011" - "CODEN: SDPAE" - "Source: Scopus" |